FDA Accepts Supplement Application for LUNSUMIO (Mosunetuzumab-axgb)
The FDA has accepted a supplemental application for LUNSUMIO, a bispecific T-cell engager.
Asset / Drug
Drug and asset intelligence for LUNSUMIO with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.